Literature DB >> 26828112

Supramolecular structure of enterobacterial wild-type lipopolysaccharides (LPS), fractions thereof, and their neutralization by Pep19-2.5.

Klaus Brandenburg1, Lena Heinbockel2, Wilmar Correa3, Satoshi Fukuoka4, Thomas Gutsmann3, Ulrich Zähringer5, Michel H J Koch6.   

Abstract

Lipopolysaccharides (LPS) belong to the strongest immune-modulating compounds known in nature, and are often described as pathogen-associated molecular patterns (PAMPs). In particular, at higher concentrations they are responsible for sepsis and the septic shock syndrome associated with high lethality. Since most data are indicative that LPS aggregates are the bioactive units, their supramolecular structures are considered to be of outmost relevance for deciphering the molecular mechanisms of its bioactivity. So far, however, most of the data available addressing this issue, were published only for the lipid part (lipid A) and the core-oligosaccharide containing rough LPS, representing the bioactive unit. By contrast, it is well known that most of the LPS specimen identified in natural habitats contain the smooth-form (S-form) LPS, which carry additionally a high-molecular polysaccharide (O-chain). To fill this lacuna and going into a more natural system, here various wild-type (smooth form) LPS including also some LPS fractions were investigated by small-angle X-ray scattering with synchrotron radiation to analyze their aggregate structure. Furthermore, the influence of a recently designed synthetic anti-LPS peptide (SALP) Pep19-2.5 on the aggregate structure, on the binding thermodynamics, and on the cytokine-inducing activity of LPS were characterized, showing defined aggregate changes, high affinity binding and inhibition of cytokine secretion. The data obtained are suitable to refine our view on the preferences of LPS for non-lamellar structures, representing the highest bioactive forms which can be significantly influenced by the binding with neutralizing peptides such as Pep19-2.5.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Antimicrobial peptides; Cytokines; Endotoxic conformation; Lipopolysaccharides; SAXS

Mesh:

Substances:

Year:  2016        PMID: 26828112     DOI: 10.1016/j.jsb.2016.01.014

Source DB:  PubMed          Journal:  J Struct Biol        ISSN: 1047-8477            Impact factor:   2.867


  5 in total

1.  Biophysical Analysis of Lipopolysaccharide Formulations for an Understanding of the Low Endotoxin Recovery (LER) Phenomenon.

Authors:  Wilmar Correa; Klaus Brandenburg; Ulrich Zähringer; Kishore Ravuri; Tarik Khan; Friedrich von Wintzingerode
Journal:  Int J Mol Sci       Date:  2017-12-16       Impact factor: 5.923

Review 2.  Inhibition of Lipopolysaccharide- and Lipoprotein-Induced Inflammation by Antitoxin Peptide Pep19-2.5.

Authors:  Lena Heinbockel; Günther Weindl; Guillermo Martinez-de-Tejada; Wilmar Correa; Susana Sanchez-Gomez; Sergio Bárcena-Varela; Torsten Goldmann; Patrick Garidel; Thomas Gutsmann; Klaus Brandenburg
Journal:  Front Immunol       Date:  2018-07-26       Impact factor: 7.561

3.  Cytokine profiles of umbilical cord blood mononuclear cells upon in vitro stimulation with lipopolysaccharides of different vaginal gram-negative bacteria.

Authors:  Edith Reuschel; Martina Toelge; Kathrin Entleutner; Ludwig Deml; Birgit Seelbach-Goebel
Journal:  PLoS One       Date:  2019-09-19       Impact factor: 3.240

4.  Anti-Infective and Anti-Inflammatory Mode of Action of Peptide 19-2.5.

Authors:  Lena Heinbockel; Günther Weindl; Wilmar Correa; Julius Brandenburg; Norbert Reiling; Karl-Heinz Wiesmüller; Tobias Schürholz; Thomas Gutsmann; Guillermo Martinez de Tejada; Karl Mauss; Klaus Brandenburg
Journal:  Int J Mol Sci       Date:  2021-02-02       Impact factor: 5.923

5.  Lipid/water interface of galactolipid bilayers in different lyotropic liquid-crystalline phases.

Authors:  Jakub Hryc; Robert Szczelina; Michal Markiewicz; Marta Pasenkiewicz-Gierula
Journal:  Front Mol Biosci       Date:  2022-08-15
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.